Metastatic liver tumors

Seminars in Surgical Oncology

Volumn 19, Issue 2, 2000, Pages 177-188

  Blumgart, Leslie H ^a,b,c,d,e   Fong, Yuman ^c,d  

^a Department of Hepatobiliary Service ^*

^b Hepatobiliary Disease Management Program

^c Memorial Hospital   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adjuvant therapy; Antineoplastic agents; Cholangiography; Colorectal neoplasms; Cryosurgery; Electrosurgery; Emission computed tomography; Incidence; Liver neoplasms; Liver surgery; Magnetic resonance imaging; Mortality; Neoplasm metastasis; Neuroendocrine tumors; Patient selection; Postoperative complications; Prognosis; Reoperation; Risk factors; Survival rate; Treatment outcome; Ultrasound; X ray computed tomography

Indexed keywords

FLUOROURACIL; FOLINIC ACID; INTERFERON; METHOTREXATE; SEMUSTINE; VINCRISTINE;

ARTICLE; CANCER MORTALITY; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; LIVER TUMOR; PRIORITY JOURNAL; PROGNOSIS; SURGICAL MORTALITY;

CHEMOTHERAPY, ADJUVANT; CHOLANGIOGRAPHY; CRYOSURGERY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE PLANNING; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033777406     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2388(200009)19:2<177::AID-SSU9>3.0.CO;2-S     Document Type: Article

References (124)

1. Surgical resection of metastatic liver tumors
2. Cancer statistics, 2000
3. Cancer statistics, 1995
4. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy
5. Prognosis of carcinoma of the large bowel in the presence of liver metastases
6. A retrospective study of the natural history of patients with liver metastases from colorectal cancer
7. Indicators of prognosis after hepatic resection for colorectal secondaries
8. The natural history of hepatic metastases from colorectal cancer: A comparison with resective treatment
9. Surgical treatment of hepatic metastases from colorectal cancers
10. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU
11. 5-FU infusion with mitomycin-C versus 5-FU infusion with methyl-CCNU in the treatment of advanced colon cancer
12. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy
13. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
14. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study
15. Interferon alpha-2a and 5fluorouracil for advanced colorectal carcinoma
16. 5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: Phase II study utilizing weekly 5-FU
17. Superiority of sequential methotrexate, flourouracil, and leucovorin of 5-flourouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group
18. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
19. Natural history of patients with untreated liver metastases from colorectal cancer
20. Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases
21. Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: A clinical and computer analysis
22. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon and rectum
23. Factors influencing survival in patients with untreated hepatic metastases
24. Carcinoma of the colon and the rectum with liver involvement
25. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma
26. Carcinoma of the colon with liver metastases
27. 5-FU infusion with methyl-CCNU in the treatment of advanced colon cancer
28. Biochemical modulation of 5-fluorouracil (FU) and liver metastases of colorectal cancer patients
29. Randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
30. A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma
31. Therapy for metastatic colorectal carcinoma with a combination of methyl-CCNU, 5-fluorouracil, vincristine and streptozotocin (MOF-strep)
32. Combination fluorouracil (FU) and recombinant alpha-interferon (IFN) in advanced colorectal carcinoma: Activity but significant toxicity
33. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A pro-spective randomized phase III trial
34. Fluorouracil and recombinant alpha-2a-interferon: An active regimen against advanced colorectal carcinoma
35. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
36. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
37. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drugresistant tumors in vitro and in vivo
38. Hepatic resection for metastases from colorectal carcinoma is of dubious value
39. Resection of hepatic metastases from colorectal cancer
40. One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinants
41. Pancreatic or liver resection for malignancy is safe and effective for the elderly
42. Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathological risk factors
43. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence
44. Hepatic resection for metastatic colorectal cancer results in cure for some patients
45. Hepatic resection for metastatic colorectal cancer
46. Late results justify resection for multiple hepatic metastases from colorectal cancer
47. Resection of colorectal liver metastases
48. Resection of liver metastases in colorectal cancer: Competitive analysis of treatment results in synchronous versus metachronous metastases
49. Patterns of failure following surgical resection of colorectal cancer liver metastases
50. Hepatic resection for metastases of the colon and rectum
51. Examination of patient selection and outcome for hepatic resection for metastatic disease
52. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection
53. A new technique for hepatic infusional chemotherapy
54. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma
55. The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases
56. Morbidity and mortality after hepatic resection of metastases from colorectal cancer
57. Liver resection for colorectal metastases
58. One hundred consecutive hepatic resections: Blood loss, transfusion and operative technique
59. Hepatic resection for colorectal liver metastases
60. Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors
61. Major hepatic resection for metachronous metastases from colon cancer
62. Pattern of recurrence in liver resection for colorectal secondaries
63. Surgical resection for hepatic and pulmonary colorectal metastases
64. Resection of hepatic and pulmonary metastases from colorectal cancer
65. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases
66. Hepatic resection in the elderly
67. Repeated hepatic resection for recurrent metastases from colorectal cancer
68. Recurrence of colorectal cancer after hepatic resection
69. Repeat hepatectomy for colorectal liver metastases
70. Repeat hepatectomy for cancer
71. Repeat liver resections from colorectal metastasis
72. Repeat hepatic resections for metastatic colorectal cancer
73. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 Cases
74. Resection of 'recurrent' colorectal metastases to the liver
75. Surgical therapy for recurrent liver metastases from colorectal cancer
76. Repeat hepatic resection as effective treatment for recurrent colorectal liver metastases
77. Repeat liver resection for recurrent colorectal metastases
78. Ninety-six five-year survivors after liver resection for metastatic colorectal cancer
79. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
80. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors
81. Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer
82. An experimental anatomical investigation of the blood and bile channels of the liver
83. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices
84. Anaesthetic experience with cryotherapy for treatment of hepatic malignancy
85. Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: A pilot study
86. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries
87. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
88. Neuroendocrine metastases of the liver
89. Resection of the liver for metastatic solid tumors
90. Cytoreductive hepatic surgery for neuroendocrine tumors
91. Hepatic resection for metastatic neuroendocrine carcinomas
92. Islet cell carcinoma of the pancreas: A twenty-year experience
93. Survival after liver resection for secondary tumors
94. Personal experience with 411 hepatic resections
95. Hepatic metastases from soft-tissue sarcoma
96. Hepatic resection for metastatic cancer
97. Hepatic resection for secondary neoplasms
98. Resection of the liver for metastatic cancer
99. Hepatic resection in 128 patients: A 24-year experience
100. Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients
101. Role of resection in the management of metastases to the liver
102. Major hepatic resection. A 25-year experience
103. Results of resection and proposed guidelines for patient selection in instances of noncolorectal hepatic metastases
104. Quantitative hypothermal method for production of local injury of tissue
105. Australian experience of cryoablation of liver tumors
106. A 5-year study of cryosurgery in the treatment of liver tumors
107. Experimental and clinical observations on hepatic cryosurgery for colorectal metastases
108. Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Preliminary results
109. Cryosurgery of liver cancer
110. Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion
111. Hand-assisted laparoscopic liver resection: Lessons from an initial experience
112. Hepatic metastases: Percutaneous radio-frequency ablation with cooled-tip electrodes
113. The liver
114. Utility of operative ultrasound in the surgical management of liver tumors
115. Neoplastic pancreaticobiliary duct obstruction: Evaluation with breath-hold MR cholangiopancreatography
116. MR cholangiopancreatography after unsuccessful or incomplete ERCP
117. Clinical value of wholebody positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer
118. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
119. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
120. Utility of 18F-FDG-PET scanning on selection of patients for resection of hepatic colorectal metastases
121. Survival of patients after co-Ionic resection for carcinoma with simultaneous liver metastases
122. Survival of patients at Pennsylvania Hospital with hepatic metastases from carcinoma of the colon and rectum
123. Survival of patients with untreated liver metastases from colorectal cancer
124. Multicentric retrospective study by the French Surgical Association